Early cytomegalovirus reactivation is associated with a poorer outcome after an alemtuzumab-based reduced-intensity conditioning allogeneic stem cell transplant

被引：0
|
作者：
Noriega, V. [1 ]
Cutino-Moguel, T. [1 ]
Zuckerman, M. [1 ]
Potter, V. [1 ]
Barabino, L. [1 ]
Raj, K. [1 ]
McLornan, D. [1 ]
de Lavallade, H. [1 ]
Devereux, S. [1 ]
Marsh, J. [1 ]
Sudhanva, M. [1 ]
Mufti, G. [1 ]
Pagliuca, A. [1 ]
机构：
[1] Kings Coll Hosp, London, England
来源：
BONE MARROW TRANSPLANTATION | 2013年 / 48卷
关键词：
D O I：
暂无
中图分类号：
Q6 [生物物理学];
学科分类号：
071011 ;
摘要：
引用
收藏
页码：S299 / S300
页数：2
相关论文
共 50 条
  • [41] Outcomes of alemtuzumab-based reduced intensity conditioning stem cell transplantation using unrelated donors for myelodysplastic syndromes
    Lim, Zi Yi
    Ho, Aloysius Y. L.
    Ingram, Wendy
    Kenyon, Michelle
    Pearce, Laurence
    Czepulkowski, Barbara
    Devereux, Stephen
    Duarte, Rafael F.
    Pagliuca, Antonio
    Mufti, Ghulam J.
    BRITISH JOURNAL OF HAEMATOLOGY, 2006, 135 (02) : 201 - 209
  • [42] Thrombotic microangiopathy after allogeneic stem cell transplantation in the era of reduced-intensity conditioning: The incidence is not reduced
    Shimoni, A
    Yeshurun, M
    Hardan, I
    Avigdor, A
    Ben-Bassat, I
    Nagler, AN
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2004, 10 (07) : 484 - 493
  • [43] Long term outcomes of adults undergoing alemtuzumab-based reduced intensity conditioning haematopoietic stem cell transplantation
    Ceesay, M. Mansour
    Lim, ZiYi
    Kenyon, Michelle
    Ho, Aloysius Y. L.
    Devereux, Stephen
    Schey, Steve
    Mijovic, Aleksandar
    Pagliuca, Antonio
    Mufti, Ghulam J.
    BLOOD, 2007, 110 (11) : 496A - 497A
  • [44] Reduced-intensity allogeneic hematopoietic stem cell transplantation with alemtuzumab conditioning regimens: survival does not plateau until after day 200
    Ho, AYL
    Kenyon, M
    El-Hemaidi, L
    Devereux, S
    Pagliuca, A
    Mufti, GJ
    BLOOD, 2003, 101 (02) : 779 - 780
  • [45] Long term outcomes of adults undergoing alemtuzumab-based reduced intensity conditioning haematopoietic stem cell transplantation
    Ceesa, M. M.
    Lim, Z. Y.
    Kenyon, M.
    Ho, A.
    Devereux, S.
    Schey, S.
    Mijovic, A.
    Pagliuca, A.
    Mufti, G. J.
    BRITISH JOURNAL OF HAEMATOLOGY, 2008, 141 : 53 - 54
  • [46] Impact of age on outcome after allogeneic hematopoietic stem cell transplantation using reduced-intensity conditioning with Fludarabine/Busulfan
    Bethge, W. A.
    Federmann, B.
    Helwig, A.
    Faul, C.
    Vogel, W.
    Kanz, L.
    ONKOLOGIE, 2012, 35 : 129 - 129
  • [47] Transplant outcome after reduced-intensity allogeneic peripheral blood stem cell transplantation is influenced by the haematopoietic stem cell recruitment procedure
    Prebet, T
    Le, QH
    Boiron, J
    Blaise, D
    Huynh, A
    Agha, IY
    Espérou, H
    Michallet, M
    BONE MARROW TRANSPLANTATION, 2006, 37 : S192 - S193
  • [48] Cytomegalovirus (CMV) reactivation after T-cell replete reduced-intensity conditioning (RIC) allogeneic hematopoietic stem cell transplantation (AHSCT) correlates with donor KIR genotype
    Sobecks, Ronald
    Askar, Medhat
    Thomas, Dawn
    Rybicki, Lisa
    Kalaycio, Matt
    Davis, Randall
    Dean, Robert
    Pohlman, Brad
    Avery, Robin
    Mossad, Sherif
    Maciejewski, Jaroslaw
    Copelan, Edward
    Bolwell, Brian
    BLOOD, 2007, 110 (11) : 873A - 874A
  • [49] No Evidence of Impact of Maraviroc on Outcome after Allogeneic Hematopoietic Stem Cell Transplant with Reduced Intensity Conditioning (RIC)
    Hammond, William Adam
    Heckman, Michael
    Finn, Laura
    Diehl, Nancy N.
    Shreders, Amanda
    Flowers, Patricia
    Roy, Vivek
    Foran, James
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2016, 22 (03) : S396 - S397
  • [50] Assessing cytomegalovirus (CMV) specific immune recovery after reduced intensity conditioning allogeneic stem cell transplantation with monoclonal antibody (Alemtuzumab).
    Lamba, R
    Myers, DG
    Popat, U
    Bollard, CM
    Carrum, G
    Krance, R
    Heslop, HE
    Brenner, MK
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 597S - 597S
12345